US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
biotech · Breast Cancer · Pleural carcinosis · SANA
Sana Biotechnology
Sana Biotechnology drug portfolio — 21 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
188 E Blaine St, Suite 400, Seattle, Washington 98102, US HQ
2018 Founded
265 Employees
Public company Type
SANA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 188 E Blaine St, Suite 400, Seattle, Washington 98102, US
- Founded
- 2018
- Employees
- 265
- Programs
- 19
- Drugs
- 21
- Patents
- 136
Sana Biotechnology pipeline
Portfolio lens on 21 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sana Biotechnology drug portfolio — 21 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Sana Biotechnology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Sana Biotechnology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Alanine racemase.
- Target
- Alanine racemase
- Mechanism
- Alanine racemase inhibitor
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in Sana Biotechnology's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Sana Biotechnology's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Sana Biotechnology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Ribonucleoside-diphosphate reductase RR1.
- Target
- Ribonucleoside-diphosphate reductase RR1
- Mechanism
- Ribonucleoside-diphosphate reductase RR1 inhibitor
-
Development asset linked to Sana Biotechnology in public FDA and regional records.
-
Development asset linked to Sana Biotechnology in public FDA and regional records.
-
Development asset linked to Sana Biotechnology in public FDA and regional records.
-
liraglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved. Molecular target: Thyroid peroxidase.
- Target
- Thyroid peroxidase
- Mechanism
- Thyroid peroxidase inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Bile acid receptor.
- Target
- Bile acid receptor
- Mechanism
- Bile acid receptor FXR agonist